Definition of Acute HCV

Definitions of Acute HCV Infection

Most commonly, acute hepatitis C virus (HCV) infection is defined as the 6-month time period following acquisition of hepatitis C virus.[1,2,3] The definition of acute hepatitis C is irrespective to whether the patient has clinical signs or symptoms of acute hepatitis.[2] The rationale for choosing 6 months as the time period to define acute infection is based on evidence that most individuals who spontaneously clear HCV will do so by 6 months.[4,5,6]

Terminology Related to Acute HCV Infection

Clinical reviews and research studies have used numerous terms to refer to acute hepatitis C infection, including acute infection, acute phase infection, very early infection, recent infection, and newly acquired infection. Overall, consensus does not exist regarding the terminology and criteria for defining acute HCV infection. Very early infection typically refers to patients with a positive HCV RNA and documented HCV antibody seroconversion, with this scenario being the most definitive for diagnosing acute HCV infection. Some experts have suggested limiting the multiple possible terms to acute infection and recent infection with the following definitions:[2]

- **Acute Infection**: estimated duration of infection less than 6 months
- **Recent Infection**: estimated duration of infection longer than 6 months, but shorter than 2 years.
Clinical Features of Acute HCV

Clinical Manifestations

Among individuals with acute HCV infection, only 15 to 25% develop a clearly distinguishable symptomatic illness.[7,8,9] In addition, most chronically infected patients cannot recall a time when they were acutely symptomatic. When patients develop symptomatic acute HCV infection, the clinical manifestations typically resemble those that occur with other types of viral hepatitis—fatigue, myalgias, low-grade fever, jaundice, dark urine, nausea, vomiting, right upper quadrant pain.[8,10] Symptoms may consist of malaise only, without jaundice or gastrointestinal symptoms (Figure 1). If symptoms from acute infection develop, they usually do so within 4 to 12 weeks (mean 7 to 8 weeks) after infection has occurred, and they typically persist for 2 to 12 weeks.[7,8,11] Fulminant hepatic failure due to acute HCV infection very rarely occurs, but preexisting chronic hepatitis B infection increases this risk.[12,13]

Relationship of Symptoms and Spontaneous Clearance

Overall, when combining data from multiple historical studies, approximately 25 to 35% of persons with acute HCV infection have spontaneous clearance of HCV.[14,15,16,17] The rates of spontaneous clearance are significantly lower (in the range of only 10 to 20%) in persons who are Black and in those individuals who have HIV coinfection.[18,19] In contrast, rates of spontaneous clearance are higher in females and in persons who acquired HCV in childhood.[20,21] It has also been demonstrated that patients who present with symptomatic acute HCV infection and jaundice have higher rates of spontaneous clearance of HCV, in the range of 35 to 50%.[8,15,22] The presence of jaundice is believed to reflect hepatic inflammation caused by a more robust initial immune response against HCV.[4,15]

Clinical Scenarios that Suggest Acute HCV Infection

Symptomatic Presentation

Individuals with acute HCV infection can develop significant symptoms and may present with the new onset of jaundice, fatigue, nausea, abdominal pain, and malaise. More often, however, these individuals have no obvious symptoms or only have limited symptoms, such as slight malaise.

History of a Recent HCV Exposure but Without Symptoms

Since acute HCV is usually asymptomatic, clinicians should test persons for HCV if they suspect a new exposure to HCV could have taken place, regardless of clinical symptoms. The most common exposures include recent injection drug use that involved needle sharing, a needlestick injury, and sexual contact with a partner who has known HCV infection. For persons with acute or recent HCV acquisition, HCV testing soon after the exposure can make the diagnosis of a new infection and distinguish acute from chronic infection. Recent injection drug use with shared needles or equipment would be considered the highest risk exposure, especially if the needle-sharing partner is known to have HCV. Although the exact risk of acquiring HCV through sexual contact is controversial, sexual transmission appears to be highest among men who have sex with men, particularly if this involves persons with HIV who have engaged in physically traumatic or rough sex.
Laboratory Diagnosis of Acute HCV

Laboratory Studies for Evaluation of Initial Infection

The key laboratory studies utilized in the evaluation of possible acute hepatitis C are HCV RNA, anti-HCV, and alanine aminotransferase (ALT). Patients who become infected with hepatitis C virus typically develop abnormal laboratory findings in the following order: detectable HCV RNA, followed by elevation in ALT, and then anti-HCV. Patients who develop a clinical illness with acute HCV infection usually have onset of symptoms well after the onset of viremia, but soon after or concomitant with increases in ALT levels.

HCV RNA (HCV Nucleic Acid Testing)

In most patients, HCV RNA can be detected in blood within 1 to 2 weeks after infection. Testing for HCV RNA is often referred to as HCV nucleic acid testing (NAT). This period from infection until HCV RNA is detectable in plasma by a commercially available assay is referred to as the previremic phase or eclipse phase. During the eclipse phase, HCV has likely established infection in susceptible hepatocytes, and, in some patients, use of qualitative HCV RNA assays with very high sensitivity will reveal blips of HCV RNA (at levels less than 10 copies/mL) in blood. The eclipse phase is followed by an 8 to 10 day “ramp-up” phase in which HCV replication increases exponentially and readily becomes detectable in plasma; the HCV RNA levels typically peak 6 to 10 weeks after infection (plateau phase) and remain near these peak levels for about 40 to 60 days. Detection of HCV RNA during acute infection is not entirely reliable as HCV RNA levels may fluctuate significantly during this period—in some instances HCV RNA levels fall below detectable levels. At the onset of symptoms, however, detectable HCV RNA levels are uniformly present. Among individuals who spontaneously clear HCV, most (73 to 86%) clear the infection within the first 6 months after HCV acquisition.

Antibodies to HCV

Antibodies to HCV typically become detectable at about 50 to 60 days after infection (range 20 to 150 days); the detection of HCV-specific antibodies significantly lags behind detectable HCV RNA levels. After 12 weeks, more than 90% of patients will have a positive HCV antibody test. The time period from initial infection until seroconversion is often referred to as the “serologic window period.” The use of only an HCV antibody test to diagnose acute HCV is not reliable, since only approximately 50 to 70% of patients have detectable HCV antibodies at the onset of symptoms. Further, a positive HCV antibody test does not differentiate acute from chronic HCV infection.

Hepatitis C Core Antigen

Several studies have shown testing for HCV core antigen can enhance the diagnostic yield of persons with acute HCV when compared with HCV antibody testing alone. The HCV antigen assays that have been developed for diagnostic purposes include HCV core antigen assays and a combination HCV antibody-HCV core antigen assay. Although some experts have proposed use of HCV core antigen testing as a less expensive option than HCV RNA testing for detecting acute HCV with similar sensitivity, there are no HCV antigen assays (or HCV antigen-antibody combination assays) that are FDA-approved for use in the United States.

Alanine Aminotransferase (ALT)

Within 4 to 12 weeks after HCV infection, most patients will have some degree of liver cell injury, as manifested by an elevation in serum ALT levels. Typically, the increases in ALT follow the presence of detectable HCV RNA levels by about 1 to 2 weeks, but generally precede the development of HCV antibodies. The mean ALT level after acute infection often reaches the 800 IU/L range. The Centers for Disease Control and Prevention uses an increase in ALT to a peak level greater than 200 IU/L during the period of acute illness.
as part of the diagnostic criteria.

**Diagnosis of Acute HCV**

In the United States, the gold standard for the laboratory diagnosis of acute HCV is an HCV antibody seroconversion (negative HCV antibody test before a suspected exposure and a positive antibody test following potential exposure), combined with a positive HCV RNA test and elevated ALT. In clinical practice, many patients do not present early enough after a potential exposure and so it is not always possible to demonstrate an initial negative antibody followed by a positive antibody. Thus, a probable diagnosis of acute HCV is made when an individual has a positive HCV RNA and evidence of a negative HCV antibody in the prior 6 months. It can be challenging to differentiate an acute infection from chronic infection in patients who have not previously undergone HCV antibody testing.

**Potential Missed Diagnosis of Acute HCV with HCV Reflex Testing Protocol**

In many laboratories in the United States, HCV testing protocols are in place whereby a positive HCV antibody test triggers automatic (reflex) testing of the sample for HCV RNA, whereas a negative initial HCV antibody test does not trigger further testing. This reflex protocol is ideal for detecting persons with chronic HCV infection and determining whether these individuals have resolved or chronic (active) infection. This protocol, however, can be problematic in the setting of acute HCV since HCV antibody seroconversion may not yet have taken place, and the HCV RNA test will not be run, thereby resulting in a false-negative HCV test. If a patient has suspected acute HCV infections, clinicians should inquire whether the laboratory performing the HCV testing uses a reflex testing protocol; if an HCV reflex testing protocol is in place, the clinician should intentionally place separate orders for the HCV antibody and the HCV RNA so that both tests will be run, regardless of the HCV antibody result. This approach, in the setting of suspected acute HCV infection, will allow for detection of HCV if the individual has not been infected with HCV long enough to have generated HCV antibodies.

**Laboratory Testing Following Known Exposure to HCV**

In situations where patients have encountered high-risk exposures, follow-up with serial laboratory testing is the key to promptly establishing the diagnosis of acute HCV infection. The following briefly outlines the recommended laboratory testing following a known exposure to hepatitis C virus (Figure 6):

- **At Initial Presentation**: HCV antibody, HCV RNA, and ALT
- **At 4 Weeks from Time of Suspected Exposure**: HCV RNA and ALT
- **At 12 Weeks from Time of Suspected Exposure**: HCV antibody, HCV RNA, and ALT
- **At 24 Weeks from Time of Suspected Exposure**: HCV antibody and HCV RNA
2020 CDC Case Definition for Acute HCV

The Centers for Disease Control and Prevention (CDC) has established criteria for the 2020 case definition of acute Hepatitis C.[36] This definition utilizes clinical criteria, laboratory criteria for diagnosis, criteria to distinguish a new case from an existing case, and a case classification (probable or confirmed). The following summarizes the 2020 CDC Case Definition for Acute HCV.[36]

Clinical Criteria

One or more of the following in a patient 36 months of age or older (unless a patient younger than 36 months of age is known to have a nonperinatal exposure):

- Jaundice, OR
- Peak elevated total bilirubin level of 3.0 mg/dL or greater, OR
- Peak elevated serum alanine aminotransferase (ALT) level greater than 200 IU/L.

AND

The absence of a more likely diagnosis (which may include evidence of acute liver disease due to other causes or advanced liver disease due to pre-existing chronic HCV infection or other causes, such as alcohol exposure, other viral hepatitis, hemochromatosis, etc.).

Laboratory Criteria for Diagnosis

Confirmatory laboratory evidence of acute HCV infection:

- A positive test for hepatitis C virus (anti-HCV)
- Hepatitis C virus detection test:
  - Nucleic acid test (NAT) for HCV RNA positive (including qualitative, quantitative or genotype testing), or
  - A positive test indicating presence of hepatitis C viral antigen(s) (HCV antigen)*.

Presumptive laboratory evidence of acute HCV infection:

- A positive test for antibodies to HCV (anti-HCV)

*When and if a test for HCV antigen(s) is approved by FDA and available.

Epidemiologic Linkage

This is not required for the case definition of acute HCV.

Criteria to Distinguish a New Case from an Existing Case

The following summarizes the criteria to distinguish a new case of HCV from an existing case of HCV.

- A new acute case is an incident acute hepatitis C case, in a person older than 36 months of age, that meets the case criteria for acute hepatitis C and has not previously been reported. Cases in patients under the age of 36 months should be classified using the Perinatal HCV Position Statement, except when the exposure is nonperinatal.[37]
- Acute cases determined by anti-HCV seroconversion do not require a positive HCV viral detection test to be considered confirmed acute cases. Similarly, new probable cases can be reclassified as confirmed cases if a positive HCV viral detection test is reported in the same reporting year.
• The CDC recommends collecting data on risk history, ranging from 2 weeks to 12 months prior to symptoms onset or diagnosis, for both probable and confirmed cases of acute HCV, with the time frame of risk history dependent on the method of acute HCV classification. For example, if a case meets the clinical criteria for acute HCV and has a positive HCV detection test, then a risk history should be obtained spanning from 2 weeks to 6 months prior to symptoms onset. Conversely, if a case is classified by conversion of an anti-HCV test or conversion of an HCV RNA test, then a risk history should be obtained spanning 2 weeks to 12 months prior to symptoms onset or HCV diagnosis.
• States and territories are encouraged to track negative HCV viral detection tests to document sustained virologic response and spontaneous clearance. If evidence of spontaneous clearance occurs after confirmation of the acute case, the case report does not need to be modified; however, subsequent negative HCV viral detection tests should be appended to case reports, as feasible, for the purposes of data analysis.
• When a case is classified as probable but lacks the criteria to allow for confirmation, a negative HCV viral detection test indicates that the case should not be classified as acute and should not be reported to the CDC. A confirmed acute case may be classified as a confirmed chronic case if a positive HCV viral detection test is reported at least one year after the onset of the acute case.

**Case Classification**

**Probable**

• A case that meets clinical criteria and has presumptive laboratory evidence,
  **AND**
• Does not have a hepatitis C virus detection test reported,
  **AND**
• Has no documentation of anti-HCV or HCV RNA test conversion within 12 months.

**Confirmed**

• A case that meets clinical criteria and has confirmatory laboratory evidence,
  **OR**
• A documented negative HCV antibody followed within 12 months by a positive HCV antibody test (anti-HCV test conversion) in the absence of a more likely diagnosis,
  **OR**
• A documented negative HCV antibody OR negative hepatitis C virus detection test (in someone without a prior diagnosis of HCV infection) followed within 12 months by a positive hepatitis C virus detection test (HCV RNA test conversion) in the absence of a more likely diagnosis.
Summary Points

- Acute HCV infection is usually defined as an estimated duration of infection less than 6 months.
- Most patients with acute HCV infection do not have a symptomatic illness or have very mild nonspecific symptoms that may include malaise, anorexia, and abdominal pain.
- In the less common situation when patients do develop symptomatic acute HCV infection, they most often present with jaundice, dark urine, nausea, abdominal pain, and malaise.
- The key laboratory studies utilized in the evaluation of possible acute hepatitis C are HCV RNA, HCV antibody, and ALT; the HCV antibody and the HCV RNA tests should be ordered simultaneously and as a separate order, not as an HCV antibody/HCV RNA reflex test.
- With acute HCV, patients usually first have detectable HCV RNA, followed by elevation in ALT, and followed last by development of HCV antibody.
- The gold standard for diagnosis is HCV antibody seroconversion combined with a positive HCV RNA test and elevated ALT.
- Acute HCV infection can rarely cause a life-threatening illness.
- The CDC 2020 case definition for acute hepatitis C includes clinical criteria, laboratory criteria, case classification as probable or confirmed, and criteria to distinguish a new case from an existing case.
Citations


References


Figures

Figure 1 Symptoms with Acute HCV Infection

This graph shows the clinical features among 51 patients with symptomatic acute HCV infection.

Figure 2 Laboratory Markers with Acute HCV Infection

Note the temporal appearance of laboratory markers typically observed with acute hepatitis C infection: HCV RNA levels first become detectable, followed by increases in ALT levels, and then detectable HCV antibody.

Source: Centers for Disease Control and Prevention (CDC).
Figure 3 Acute HCV Infection: Eclipse Phase

The eclipse phase is the time between HCV infection and the appearance of detectable HCV RNA.

Source: Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994-1002.
**Figure 4 Acute HCV Infection: Viral Dynamics**

This graph illustrates early phases of viral dynamics observed following acquisition of HCV: eclipse, ramp up, and plateau.

Source: Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994-1002.
**Figure 5 Acute HCV Infection: Serologic Window Period**

The serologic window period is the time between HCV infection and clinically detectable HCV antibodies. The window period with HCV infection is typically 50 to 60 days.
Figure 6 Laboratory Evaluation for Persons Exposed to HCV

Note: for prior infection, this may be due either to spontaneous clearance of HCV or following a sustained virology response after treatment.